Management of metastatic renal cell carcinoma: current trends

References

• Mancuso A, Sternberg CN. New treatment approaches in metastatic renal cell carcinoma. Curr. Opin. Urol.16(5), 337–341 (2006).
   PubMedGoogle Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin.58(2), 71–96 (2008)
   PubMed Web of Science ®Google Scholar
• Hutson TE, Figlin RA. Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park, NY) 21(10), 1175–1180 (2007)
   Google Scholar
• Zisman A, Belldegrun AS, Figlin RA. Urinary tract cancers. In: Manual of Clinical Oncology (5th Edition). Casciato DA (Ed.). Lippincott Williams & Wilkins, PA, USA, 295–320 (2004).
   Google Scholar
• Motzer RJ, Russo P, Nanus DM, Berg WJ. Renal cell carcinoma. Curr. Probl. Cancer21(4), 185–232 (1997).
   PubMed Web of Science ®Google Scholar
• Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs67(9), 1257–1264 (2007).
   PubMedGoogle Scholar
• Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial Sloan–Kettering cancer center experience. Clin. Cancer Res.10(18 Pt 2), 6302S–6303S (2004).
   PubMedGoogle Scholar
• Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan–Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol.23(4), 832–841 (2005).
   PubMed Web of Science ®Google Scholar
• Robson CJ. Radical nephrectomy for renal cell carcinoma. J. Urol.89, 37–42 (1963).
   PubMed Web of Science ®Google Scholar
• Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J. Urol.167(3), 1295–1298, (2002).
   PubMed Web of Science ®Google Scholar
• Schafhauser W, Ebert A, Brod J, Petsch S, Schrott KM. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy. Anticancer Res.19(2C), 1573–1578, (1999).
   Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med.345(23), 1655–1659 (2001)
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358(9286), 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N. Engl. J. Med.345(23), 1711–1712 (2001)
   PubMed Web of Science ®Google Scholar
• Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J. Clin. Oncol.16(6), 2261–2266 (1998).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med.313(23), 1485–1492 (1985).
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Français d’Immunothérapie. N. Engl. J. Med.338(18), 1272–1278 (1998).
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol.21(16), 3127–3132 (2003).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol.23(1), 133–141 (2005).
   PubMed Web of Science ®Google Scholar
• Negrier S, Perol D, Ravaud A et al. Medroxyprogesterone, interferon α-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer110(11), 2468–2477 (2007)
   PubMed Web of Science ®Google Scholar
• Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. (1), CD001425 (2005).
   Google Scholar
• Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology105(1), 31–57 (1995).
   PubMed Web of Science ®Google Scholar
• Basche B. A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage. JAMA295(21), 2537–2538 (2006).
   Google Scholar
• Melmon KL, Rosen SW. Lindau’s disease. Review of the literature and study of a large kindred. Am. J. Med.36, 595–617 (1964).
   PubMed Web of Science ®Google Scholar
• Linehan WM, Vasselli J, Srinivasan R et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin. Cancer Res.10(18 Pt 2), 6282S–6829S (2004).
   PubMed Web of Science ®Google Scholar
• Izzedine H, Billemont B, Thibault F, Rixe O. New challenges in kidney cancer therapy: sunitinib. Ann. Oncol.18(Suppl. 9), ix83–ix86 (2007).
   Google Scholar
• Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol.23(5), 1028–1043 (2005).
   PubMed Web of Science ®Google Scholar
• Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1α ubiquitination by a reconstituted von Hippel–Lindau (VHL) tumor suppressor complex. Proc. Natl Acad. Sci. USA97(19), 10430–10435 (2000).
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol.19(3), 843–850 (2001).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349(5), 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Kabbinavar FF, Figlin RA et al. Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol.25(29), 4536–4541 (2007)
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. (2008) (Epub ahead of print).
   Google Scholar
• Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis7(3), 193–201 (2004).
   PubMedGoogle Scholar
• Granger JP, Alexander BT. Abnormal pressure-natriuresis in hypertension: role of nitric oxide. Acta Physiol. Scand.168, 161–168 (2000).
   PubMedGoogle Scholar
• Ostendorf T, Kunter U Eitner F. VEGF mediates glomerular endothelial repair. J. Clin. Invest.104, 913–923 (1999)
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Kabbinvar FF, Schulz J, McLeod M. Addition of bevacizumab to bolus 5FU/leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol.23, 3697–3705 (2005).
   PubMedGoogle Scholar
• Scappaticci FA, Fehrenbacher L, Cartwright T. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol.91, 173–180 (2005).
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol.24(1), 25–35 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24(1), 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295(21), 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Motzer RJ, Michaelson MD et al. Sunitinib therapy for patients with metastatic renal cell carcinoma (mRCC). Updated results of two Phase II trials and prognostic factor analysis for survival. Proc. Am. Soc. Clin. Oncol.25, 5095 (2007)
   Google Scholar
• Harshman L, Srinivas S. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer. Onkologie31(8–9), 432–433 (2008).
   PubMed Web of Science ®Google Scholar
• Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol.26(22), 3743–3748 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Grünwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie30(10), 519–524 (2007)
   PubMedGoogle Scholar
• Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica148(2), 90–92 (1974).
   PubMedGoogle Scholar
• Sutent. Summary of product characteristics. Pfizer Inc, NY, USA (2008).
   Google Scholar
• Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am. J. Health Syst. Pharm.65(2), 123–131 (2008)
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92(3), 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Gollob JA, Rathmell WK, Richmond TM et al. Phase II trial of sorafenib plus interferon α-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol.25(22), 3288–3295 (2007).
   PubMed Web of Science ®Google Scholar
• Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer Inst.100(20), 1454–1463 (2008).
   PubMed Web of Science ®Google Scholar
• Schrader AJ, Hofmann R. Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anticancer Drugs19(3), 235–245 (2008).
   Google Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22(5), 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Jac J, Giessinger S, Khan M,Willis J, Chiang S, Amato R. A Phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). J. Clin. Oncol.25 (2007) (Abstract 5107).
   Google Scholar
• Amato RJ, Misellati A, Khan M, Chiang S. A Phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J. Clin. Oncol.24(Suppl.) (2006) (Abstract 4530).
   PubMedGoogle Scholar
• Patard JJ. Tyrosine kinase inhibitors in clinical practice: patient selection. Eur. Urol. Suppl.7(9) 601–609 (2008).
   Google Scholar